Results 121 to 130 of about 7,233,987 (192)

Pain medication use in patients with X-linked hypophosphatemia treated with burosumab: a retrospective real-world study. [PDF]

JBMR Plus
Macica CM, Li Z, Johnson B, Noman A, Park C, Woods GN.   +5 more
europepmc   +1 more source

Correction: Experts' consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan. [PDF]

J Endocrinol Invest
Baroncelli GI, Barale M, Brandi ML, Camozzi V, Carrara S, Nicoletti MC, Castellano E, Cetani F, Comberiati P, Iorgi ND, Eller-Vainicher C, Emma F, Fintini D, Giannini S, Gianotti L, Grandone A, Grassi G, Mora S, Palermo A, Pigliaru F, Pitea M, Procopio M, Rochira V, Ruggeri RM, Ruggiero B, Stagi S, Vezzoli G, Corbetta S.   +27 more
europepmc   +1 more source

Case Report: Deep intronic <i>PHEX</i> variant causing aberrant splicing identified by whole genome and targeted RNA sequencing in X-linked hypophosphatemia. [PDF]

Front Endocrinol (Lausanne)
Spranger S, Faust H, Duffek P, Schubert S, Skladny H, Kovacs P, Tönjes A, Popp D.   +7 more
europepmc   +1 more source

Effectiveness, safety, and pharmacokinetics of burosumab in Chinese children with X-linked hypophosphatemia: an open-label, single-arm phase 4 study. [PDF]

JBMR Plus
Wu W, Jiang Y, Zhang Z, Liu L, Qiu W, Ji Y, Sugimoto M, Yung C, Qiu C, Kuriki M, Luo X, Xia W.   +11 more
europepmc   +1 more source

Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program.

J Clin Endocrinol Metab
Ward LM, Carpenter TO, Cassinelli H, Florenzano P, Imel EA, Khan AA, Johnson B, Yang E, Vincent M, Heerssen HM, Li Z, Simmons JH.   +11 more
europepmc   +1 more source

What is it like living with X-linked hypophosphatemia?: results from an Australian consumer survey. [PDF]

JBMR Plus
Sandy JL, Ford N, Bevc S, Rodda C, Siafarikas A, Simm PJ, Collins L, Wall CL, Biggin A, Munns CF.   +9 more
europepmc   +1 more source

Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D. [PDF]

Pediatr Nephrol
Przygodda S, Brieger LC, Bohlen AV, Rehberg M, Konrad M, Schlingmann KP, Hiort O, Schmidt D, John-Kroegel U, Wühl E, Kemper MJ, Derichs U, Patzer L, Albers N, Dunstheimer D, Heger S, Grohmann-Held K, Schroeder C, Jorch N, Schmid E, Staude H, Weitz M, Lecher L, Freiberg C, Huebner A, Heitmeyer-Pyper A, Sparta G, Evers K, Ostendorf AJ, Partsch CJ, Marx M, Land C, Baus I, Wilkening F, Moeller K, Simic-Schleicher G, Empting S, Müller D, Metzing O, Wagner V, Holder M, Žebec MS, Schnabel D, Haffner D, Živičnjak M, German Society for Pediatric Nephrology (GPN), the German Society for Pediatric, Adolescent Endocrinology, Diabetology (DGPAED).   +48 more
europepmc   +1 more source

Correction to: Health-related quality of life in French adults with X-linked hypophosphatemia: real-world data from the International XLH Registry. [PDF]

JBMR Plus
europepmc   +1 more source

Impact of oral phosphate supplements and active vitamin D treatment on dentoalveolar features of X-linked hypophosphatemia. [PDF]

JBMR Plus
Po J, Lira Dos Santos EJ, François A, Cauliez A, Zhukouskaya VV, Linglart A, Chaussain C, Bardet C.   +7 more
europepmc   +1 more source

Burosumab in adults with X-linked hypophosphatemia: real-world experience from a retrospective study in Sydney. [PDF]

JBMR Plus
Kumar S, Girgis CM, Tran B, Alvarez M, Clifton-Bligh RJ.   +4 more
europepmc   +1 more source